Kalyanasundaram Subramanian - Taro Pharmaceutical CEO and Director
| TARO Stock | USD 42.05 0.07 0.17% |
CEO
Mr. Kalyanasundaram Subramanian is redesignated as Director of the Company effective April 1, 2017. He was Chief Executive Officer, Director of Taro Pharmaceutical Industries Ltd., effective August 1, 2013. Mr. Sundaram was Chairman of the Taro Board from April 2012 until he was appointed Chief Executive Officer. He was Sun Pharmas Chief Executive Officer from April 2010 to April 2012, and in this role he focused on accelerating Sun Pharmas growth in India and other emerging market countries and developing broad, strategic alliances with other leading companies in the pharmaceutical industry since 2017.
| Age | 62 |
| Tenure | 7 years |
| Address | 14 Hakitor Street, Haifa, Israel, 2624761 |
| Phone | 972 4 847 5700 |
| Web | https://www.taro.com |
Taro Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0103 % which means that it generated a profit of $0.0103 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0261 %, meaning that it created $0.0261 on every $100 dollars invested by stockholders. Taro Pharmaceutical's management efficiency ratios could be used to measure how well Taro Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of April 2024, Return On Tangible Assets is likely to grow to 0.28. Also, Return On Capital Employed is likely to grow to 0.41. At this time, Taro Pharmaceutical's Net Tangible Assets are very stable compared to the past year. As of the 17th of April 2024, Return On Tangible Assets is likely to grow to 0.28, though Other Current Assets are likely to grow to (1.1 K).Similar Executives
| Found 3 records | CEO Age | ||
| Daniel AbdunNabi | Emergent Biosolutions | 62 | |
| Kevin Gorman | Neurocrine Biosciences | 66 | |
| Joseph Papa | Emergent Biosolutions | 68 | |
Management Performance
| Return On Equity | 0.0261 | ||||
| Return On Asset | 0.0103 |
Taro Pharmaceutical Leadership Team
Elected by the shareholders, the Taro Pharmaceutical's board of directors comprises two types of representatives: Taro Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Taro. The board's role is to monitor Taro Pharmaceutical's management team and ensure that shareholders' interests are well served. Taro Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Taro Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erik Zwicker, Vice President General Counsel, Secretary | ||
| Avi Avramoff, Global Vice President - Research & Development | ||
| Chantal LeBlanc, Vice President - Head of Quality | ||
| Robert Stein, Independent Director | ||
| Mariana Bacalu, Group Vice President - Quality Affairs | ||
| Jeff Holm, Executive Director Sales and Operations of Branded Pharmaceutical business | ||
| Mariano Balaguer, CFO, Chief Accounting Officer, Vice President | ||
| Daryl LeSueur, Vice President - Head of Operations, Brampton | ||
| Erik JD, General VP | ||
| Rami Zajicek, Group Vice President Haifa Site Manager | ||
| Ralph Bohrer, Executive Director, Sales and Marketing, TPHA | ||
| Danny Biran, Independent Director | ||
| Ilana AvidovMor, Independent Director | ||
| Itamar Karsenti, Vice President - Head of Operations, Haifa | ||
| James Kedrowski, Director | ||
| Uday Baldota, Chief Executive Officer, Director | ||
| Aalok Shanghvi, Director | ||
| Kalyanasundaram Subramanian, CEO and Director | ||
| Roman Kaplan, Vice Manager | ||
| William Coote, Vice President Treasurer | ||
| Ori Gutwerg, Vice President - Head of US Generics Rx | ||
| Michael Perfetto, Group VP and Chief Commercial Officer of the Generic Rx Bus., U.S.A. | ||
| Brant Schofield, Vice President - Sales & Marketing, TPHA, U.S.A. | ||
| Ara Aprahamian, Vice President - Sales and Marketing | ||
| Michael Teiler, Group Vice President - Portfolio Management | ||
| Daphne Huang, Chief Financial Officer, Chief Accounting Officer, Vice President | ||
| Victoria Chester, Vice President - Head of Quality | ||
| Abhay Gandhi, Vice Chairman of the Board | ||
| Elhanan Streit, Independent Director | ||
| Jayesh Shah, Head of Procurement | ||
| Sudhir Valia, Director | ||
| Dilip Shanghvi, Chairman of the Board | ||
| Richard Glaze, Vice President - Head of Information Technology | ||
| Michael Kalb, Interim CFO, Group Vice President Chief Accounting Officer; CFO of Taro U.S.A. | ||
| Stephen Manzano, Interim General Counsel, Vice President of Corporate Compliance | ||
| Sunil Mehta, Group Vice President General Manager - Canadian operations | ||
| Vikash Agarwal, Vice President - Head of Business Development | ||
| Linda Benshoshan, Independent Director | ||
| Michele Visosky, Vice President - Head of Human Resources | ||
| Itzik Baruch, Vice Services | ||
| Dov Pekelman, Independent Director |
Taro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Taro Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0261 | ||||
| Return On Asset | 0.0103 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 680.86 M | ||||
| Shares Outstanding | 37.58 M | ||||
| Shares Owned By Insiders | 78.48 % | ||||
| Shares Owned By Institutions | 13.45 % | ||||
| Number Of Shares Shorted | 39.81 K | ||||
| Price To Earning | 14.57 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Taro Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Taro Pharmaceutical's short interest history, or implied volatility extrapolated from Taro Pharmaceutical options trading.
Currently Active Assets on Macroaxis
| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink | |
| XLM | Stellar | |
| CRO | Cronos |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taro Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Taro Stock analysis
When running Taro Pharmaceutical's price analysis, check to measure Taro Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taro Pharmaceutical is operating at the current time. Most of Taro Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Taro Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taro Pharmaceutical's price. Additionally, you may evaluate how the addition of Taro Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Taro Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taro Pharmaceutical. If investors know Taro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taro Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.782 | Earnings Share 1.22 | Revenue Per Share 16.252 | Quarterly Revenue Growth 0.129 | Return On Assets 0.0103 |
The market value of Taro Pharmaceutical is measured differently than its book value, which is the value of Taro that is recorded on the company's balance sheet. Investors also form their own opinion of Taro Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Taro Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taro Pharmaceutical's market value can be influenced by many factors that don't directly affect Taro Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taro Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taro Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taro Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.